Advaxis, Inc.
(NASDAQ : ADXS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.90%194.181.2%$592.16m
GILDGilead Sciences, Inc.
-0.83%69.200.9%$496.51m
BIIBBiogen Inc.
0.72%324.051.3%$476.94m
CELGCelgene Corporation
-0.47%69.651.2%$474.00m
ILMNIllumina, Inc.
0.13%319.933.5%$402.89m
REGNRegeneron Pharmaceuticals, Inc.
1.08%345.332.6%$297.08m
VRTXVertex Pharmaceuticals Incorporated
-0.94%165.111.9%$277.86m
ALXNAlexion Pharmaceuticals, Inc.
-0.89%118.622.0%$201.35m
AAgilent Technologies, Inc.
0.42%64.991.5%$188.27m
EXASExact Sciences Corporation
3.65%71.3825.3%$147.45m
SRPTSarepta Therapeutics, Inc.
0.07%119.0415.4%$145.09m
LGNDLigand Pharmaceuticals Incorporated
1.68%154.4623.3%$145.09m
ECYTEndocyte, Inc.
0.25%23.672.0%$124.13m
INCYIncyte Corporation
2.28%66.512.5%$117.76m
NKTRNektar Therapeutics
0.11%38.235.6%$117.70m

Company Profile

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.